SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
POS AM - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This site also streamlines access to critical information and resources for investors, partners, patients, providers, and other key stakeholders. The redesigned website provides a significantly enhanced user experience, ensuring that each stakeholder group can easily navigate and find relevant information. Investor
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company's clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists' (FMS) retail clinical location at the Meijer Supercenter in McHenry, Illinois. Expanding Access in the Midwest Meijer, a privately owned and family-operated retailer based in Michigan, has more than 500 locations in the heartland of America. The company's consumers are predominately middle-aged and older adults in suburban and rural areas of the Midwest. Given that 73% of Meijer shoppers are within the Gen X and Boomers age groups of 45-years old and older, it is cruci
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare sectors, including hospitals, health systems, health plans, and employer plans. The event is focused on enabling employers to build, launch, and optimize onsite clinical care facilities that are innovative and effective for their employees. Employee Onsite Clinics Drive Cost-Savings The prevalence of onsite clinics
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Mayumi Kitakata, a 57-year-old resident of Tokyo, Japan, is among the many pet owners who have turned to artificial intelligence to ensure the well-being of their furry companions. What Happened: Kitakata, who is concerned about the health of her 14-year-old cat, Chi, has adopted CatsMe!, an AI-driven smartphone application that claims to detect feline pain, reported Reuters. Kitakata, who has had cats since her mid-20s, uses the app to monitor Chi’s urinal activity and facial expressions. She believes that if she had used CatsMe! with her previous cat, Soran, she might have been able to detect his cancer earlier and potentially save him. See Also: Apple Analyst Says ‘You Don’t Wann
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical